Amgen Psoriasis Drug Brodalumab Tops J and J's UstekinumabAmgen Psoriasis Drug Brodalumab Tops J and J's Ustekinumab

Amgen Inc said on Tuesday that its experimental psoriasis drug, brodalumab, met all the goals of a late-stage study, clearing the rough skin patches associated with the disease more thoroughly than Johnson & Johnson's (ustekinumab) Stelara and a placebo. Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Source Type: news